Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$139.02 USD

139.02
2,616,684

+10.04 (7.78%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

by Zacks Equity Research

Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.

Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?

by Zacks Equity Research

Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.

Factors Expected to Influence Microsoft's (MSFT) Q2 Earnings

by Zacks Equity Research

Microsoft's (MSFT) Q2 results gains from enterprise strength, robust Office 365 & Azure adoption.

Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)

by Zacks Equity Research

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.

Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings?

by Zacks Equity Research

Align Technology (ALGN) is likely to gain from strength in Invisalign space as well as Scanner and Service business in fourth-quarter 2018.

ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio

by Zacks Equity Research

ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.

Quest Diagnostics' Core Diagnostics Strong Amid Several Woes

by Zacks Equity Research

Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.

Neogen Gains on Strong Genomic Arm Amid Stiff Competition

by Zacks Equity Research

Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.

Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know

by Zacks Equity Research

Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is Why Growth Investors Should Buy Illumina (ILMN) Now

by Zacks Equity Research

Illumina (ILMN) could produce exceptional returns because of its solid growth attributes.

Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?

by Zacks Equity Research

Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.

Henry Schein Animal Health Spin-Off Approaches, Cost Mounts

by Zacks Equity Research

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Illumina (ILMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed at $305.63 in the latest trading session, marking a +0.05% move from the prior day.

The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

Why You Should Consider Buying Omnicell (OMCL) Stock Now

by Zacks Equity Research

Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.

Swarup Gupta headshot

5 Great Medical Stocks to Buy Ahead of Q4 Earnings

by Swarup Gupta

A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.

QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

by Zacks Equity Research

QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.

Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed the most recent trading day at $307.89, moving +1.72% from the previous trading session.

Urmimala Biswas headshot

3 Medical Stocks Likely to Emulate Illumina's Success in 2019

by Urmimala Biswas

Illumina's (ILMN) gains are indeed staggering. But is it the sole star in the firmament setting benchmarks for others to try and emulate?

Here's Why You Should Buy Express Scripts (ESRX) Stock Now

by Zacks Equity Research

Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.